LuPIN trial data will be presented by A/Professor Louise Emmett at the ASCO GU Conference in San Francisco 13-15 Feb 2020, according to the NOX website
GK said at the last AGM that the LuPIN trial was great value for money, costing just $5,000 per patient; and that data so far for LuPSMA + NOX66 was clearly superior to LuPSMA alone. I expect to see that superiority reinforced in the February presentation.
LuPIN
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
